Jasub Property Holdings LLP has disclosed its acquisition of 51,00,000 equity shares, representing 1.33% of the total share capital, in Cohance Lifesciences Limited. This transaction, conducted via inter-se transfer through Block Deals on November 09-11, 2026, brings Jasub Property Holdings LLP’s total holding to 6.36%. The acquisition impacts the shareholding pattern of Cohance Lifesciences.
Significant Share Acquisition in Cohance Lifesciences
Jasub Property Holdings LLP has officially announced the acquisition of a substantial stake in Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited). The disclosure, made pursuant to Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, details the purchase of 51,00,000 equity shares, translating to 1.33% of the company’s total voting capital. This transaction occurred between November 09, 2026, and November 11, 2026, through inter-se transfer via Block Deals.
Updated Holding Details
Following this acquisition, Jasub Property Holdings LLP’s total holding in Cohance Lifesciences has increased to 2,43,26,009 shares, constituting 6.36% of the total equity share capital. The acquisition was executed without any change in the encumbrance status of the shares. The filing also outlines the pre-acquisition and post-acquisition shareholding of various entities associated with the acquirer, including Jasti Property and Equity Holdings Private Limited, Mrs. Venkata Subbamma Jasti, Mr. Venkateswarlu Jasti, and Mrs. Sudharani Jasti. The total diluted share capital of the target company post-acquisition stands at 40,59,80,385 shares.
Source: BSE
